Latest Clinical Trials
Trial of Therapeutic Hypothermia in Patients With ARDS University of Maryland, Baltimore NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments University of British Columbia NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis The Cleveland Clinic NA
RECRUITING
(Sep 1, 2026)
PHASE3 Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) Baylor College of Medicine NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE2 Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) Baylor College of Medicine NA
RECRUITING
(Sep 1, 2026)
PHASE1 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain AFT Pharmaceuticals, Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Dana-Farber Cancer Institute NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity Eli Lilly and Company NA
RECRUITING
(Sep 1, 2026)
PHASE1 Post-Vasectomy Pain Study Columbia University NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Merck Sharp & Dohme LLC NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 6, 2026)
PHASE2 Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL Baylor College of Medicine NA
COMPLETED
(Aug 1, 2026)
PHASE1 Paracetamol and Pharmacogenetic University Hospital, Clermont-Ferrand NA
COMPLETED
(Aug 1, 2026)
PHASE1 Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine University Hospital, Clermont-Ferrand NA
COMPLETED
(Aug 1, 2026)
PHASE1 Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Efficacy of Different Drugs to Control Post Root Canal Treatment Pain University of Khartoum NA
COMPLETED
(Aug 1, 2026)
PHASE2 FIGHT-RP 1 Extension Study Johns Hopkins University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Opioid Analgesic Reduction Study Rutgers, The State University of New Jersey NA
COMPLETED
(Aug 1, 2026)
PHASE3 Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants Mount Sinai Hospital, Canada NA
RECRUITING
(Aug 1, 2026)
PHASE2 Therapies for Down Syndrome Regression Disorder University of Colorado, Denver NA
COMPLETED
(Aug 1, 2026)
PHASE2 NSAID Use After Robotic Partial Nephrectomy University of Miami NA
RECRUITING
(Aug 1, 2026)
PHASE2 Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE1 Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy Brigham and Women's Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE2 Patient Controlled Administration of Liquid Acetaminophen Yale University NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients Rutgers, The State University of New Jersey NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome Brigham and Women's Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI) Val Adams NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant Novo Nordisk A/S NA
RECRUITING
(Aug 1, 2026)
PHASE1 Maxigesic for Postoperative Pain Control After Laparoscopic or Robotic Gastrectomy Seoul National University Bundang Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Buprenorphine for the Management of Pain in Children With Sickle Cell Disease Natasha Archer NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Sac-TMT in Vaginal and Vulvar Cancers Latin American Cooperative Oncology Group NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Alliance for Clinical Trials in Oncology NA
COMPLETED
(Jul 1, 2026)
PHASE3 SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation Weill Medical College of Cornell University NA
COMPLETED
(Jul 1, 2026)
PHASE2 Epidural Analgesia for Pancreatitis (Epipan Study) University Hospital, Clermont-Ferrand NA
COMPLETED
(Jul 1, 2026)
PHASE3 Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 T-Cell Therapy for Advanced Breast Cancer Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study of Oxidative Pathways in MS Fatigue University of California, San Francisco NA
COMPLETED
(Jul 1, 2026)
PHASE2 Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) National Cancer Institute (NCI) NA
COMPLETED
(Jul 1, 2026)
PHASE1 C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Pediatric Brain Tumor Consortium NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy Yale University NA
COMPLETED
(Jul 1, 2026)
PHASE2 Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas Baylor College of Medicine NA
RECRUITING
(Jul 1, 2026)
PHASE1 Pain After Strabismus Surgery Ann & Robert H Lurie Children's Hospital of Chicago NA
SUSPENDED
(Jul 1, 2026)
PHASE2 Optimizing Pain Treatment in Children On Mechanical Ventilation Weill Medical College of Cornell University NA
RECRUITING
(Jul 1, 2026)
PHASE3 RADA16 for Adult Tonsillectomy Rutgers, The State University of New Jersey NA
RECRUITING
(Jul 1, 2026)
PHASE3 R.E.C.K vs Exparel in Robotic Nephrectomy Wake Forest University Health Sciences NA
RECRUITING
(Jul 1, 2026)
PHASE3 Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children Rutgers, The State University of New Jersey NA
RECRUITING
(Jul 1, 2026)
PHASE2 NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma Baylor College of Medicine NA
RECRUITING
(Jul 1, 2026)
PHASE1 An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service University of California, San Francisco NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Probiotic Supplements in Osteoarthritis Beni-Suef University NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity Pfizer NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer Henan Cancer Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 The Anesthetic and Analgesic Effect of Adjunct Liposomal Bupivacaine in Periodontal Surgical Procedures The University of Texas Health Science Center at San Antonio NA
COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 Methoxyflurane Versus Usual Care for Non-Traumatic Pain in Emergency Departments University Hospital, Tours NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy University of Wisconsin, Madison NA
COMPLETED
(Jun 1, 2026)
PHASE2 The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Adrienne G. Waks NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial Washington University School of Medicine NA
COMPLETED
(Jun 1, 2026)
PHASE2 TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. Baylor College of Medicine NA
RECRUITING
(Jun 1, 2026)
PHASE1 Comparison of an Inhaled Sedation Strategy to an Intravenous Sedation Strategy in Intensive Care Unit Patients Treated With Invasive Mechanical Ventilation University Hospital, Brest NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Reducing Opioid Use and Misuse After Wisdom Molar Extractions Rutgers, The State University of New Jersey NA
SUSPENDED
(Jun 1, 2026)
PHASE2 Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone Stanford University NA
RECRUITING
(Jun 1, 2026)
PHASE2 Oral N-acetylcysteine for Retinitis Pigmentosa Johns Hopkins University NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy Wake Forest University Health Sciences NA
TERMINATED
(Jun 1, 2026)
PHASE2, PHASE3 Siplizumab for Sickle Cell Disease Transplant Columbia University NA
TERMINATED
(Jun 1, 2026)
PHASE1, PHASE2 MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. Masonic Cancer Center, University of Minnesota NA
RECRUITING
(Jun 1, 2026)
PHASE2 Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults Sanaria Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE1 Non-Narcotic Pain Control After ACL Reconstruction The Cleveland Clinic NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Jaw Muscle Pain Post Wisdom Molar Surgery Rutgers, The State University of New Jersey NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC Beijing Biotech NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Vaccination With Flt3L, Radiation, and Poly-ICLC Icahn School of Medicine at Mount Sinai NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Study of Post-Herniorrhaphy Non-opioid MMA Regimens Heron Therapeutics NA
COMPLETED
(May 1, 2026)
PHASE3 KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) Merck Sharp & Dohme LLC NA
COMPLETED
(May 1, 2026)
PHASE2 ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter M.D. Anderson Cancer Center NA
TERMINATED
(May 1, 2026)
PHASE2 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Zonisamide Versus Topiramate in Migraine Kafrelsheikh University NA
COMPLETED
(May 1, 2026)
PHASE3 Dexamethasone for Ureteral STent Symptoms (DUSTS) The Methodist Hospital Research Institute NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome Children's Hospital of Fudan University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus University of South Alabama NA
TERMINATED
(Apr 1, 2026)
PHASE2 Post-Op Pain Control for Prophylactic Intramedullary Nailing. St. Louis University NA
RECRUITING
(Apr 1, 2026)
PHASE3 PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients Beth Israel Deaconess Medical Center NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Study of N-acetylcysteine in Patients With COVID-19 Infection Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer University of Wisconsin, Madison NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain Johns Hopkins University NA
COMPLETED
(Apr 1, 2026)
PHASE3 Herniorrhaphy for Postoperative Pain Cali Pharmaceuticals LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 CPL-01 in the Management of Postoperative Pain After Bunionectomy Cali Pharmaceuticals LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Johnson & Johnson Consumer Inc. (J&JCI) NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants Eli Lilly and Company NA
COMPLETED
(Apr 1, 2026)
PHASE1 Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity University of South Alabama NA
COMPLETED
(Apr 1, 2026)
PHASE1 Efficacy of Rifaximin With NAC in IBS-D Mark Pimentel, MD NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects Fujian Shengdi Pharmaceutical Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE1 Opioid-Sparing Joint Replacement Emory University NA
RECRUITING
(Apr 1, 2026)
PHASE3 Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen Wake Forest University Health Sciences NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight Novo Nordisk A/S NA
RECRUITING
(Apr 1, 2026)
PHASE1 Comparison of Acetaminophen With Aminophylline and Aminophylline With Dexamethasone for Prophylaxis of PDPH in Patients With History of PDPH. Sargodha Medical College NA
COMPLETED
(Apr 1, 2026)
PHASE2 Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis The Fourth Affiliated Hospital of Zhejiang University School of Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Endovenous Laser Ablation With 1940 nm Versus 1470 nm Kafrelsheikh University NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma University of Miami NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture Mayo Clinic NA
RECRUITING
(Mar 1, 2026)
PHASE2 Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Benjamin T Diamond, MD NA
RECRUITING
(Mar 1, 2026)
PHASE2 Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population Texas Scottish Rite Hospital for Children NA
RECRUITING
(Mar 1, 2026)
PHASE2 The SCOPE Trial: Sleep, Cognition, and Pain Bundle vs. ERAS-cardiac for Postoperative Delirium Beth Israel Deaconess Medical Center NA
RECRUITING
(Mar 1, 2026)
PHASE3 Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain Contineum Therapeutics NA
COMPLETED
(Mar 1, 2026)
PHASE1 Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2